NCT03211078

Brief Summary

With the increased incidence of lung cancer and prevalence of low dose CT screening, treating of early lung cancer has becoming an important issue in the clinical practice of thoracic oncology. In this clinical study, the investigators will evaluate whether superDimension (superD) ENB (Electromagnetic navigation bronchoscopy) in combination with interstitial photodynamic therapy can provide the chance of tumor eradication.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable lung-cancer

Timeline
Completed

Started Oct 2016

Shorter than P25 for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 14, 2016

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

July 5, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 7, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2017

Completed
Last Updated

July 12, 2017

Status Verified

July 1, 2017

Enrollment Period

11 months

First QC Date

July 5, 2017

Last Update Submit

July 9, 2017

Conditions

Keywords

Early lung cancerPhotodynamic therapyENB

Outcome Measures

Primary Outcomes (1)

  • Disease-free survival

    The time interval between enrollment and the earliest onset of any of the following events,: tumor local recurrence , distant metastasis, and mortality

    5 years

Secondary Outcomes (3)

  • post-operative complication

    3 month

  • post-operative pulmonary function

    6, 12, and 24 months

  • overall survival

    5 years

Study Arms (1)

super-D ENB guided-PDT

EXPERIMENTAL

To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.

Procedure: super-D ENB guided-PDT

Interventions

PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.

super-D ENB guided-PDT

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Multiple small lung cancer which cannot be completely removed by surgical resection.
  • Patient with small early lung cancer with diameter less than 1 cm and with high surgical risk precluding surgery.
  • Patient with small early lung cancer with diameter less than 1 cm but unwilling to receive surgical intervention.
  • Age above 20 years old and who can do the bronchoscopy test

You may not qualify if:

  • \. Bleeding tendency. 2 .Poor cardiopulmonary function with intolerance to bronchoscopy examination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Zhongzheng Dist., 100, Taiwan

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Jang-Ming Lee, MD. PhD.

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jang-Ming Lee, MD. PhD.

CONTACT

Peiwen Yang, PhD.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 5, 2017

First Posted

July 7, 2017

Study Start

October 14, 2016

Primary Completion

September 1, 2017

Study Completion

September 15, 2017

Last Updated

July 12, 2017

Record last verified: 2017-07

Locations